180 results on '"de Mestier, Louis"'
Search Results
2. Prospective observational study on biomarkers of response in pancreatic ductal adenocarcinoma
3. The Need for Centralization for Small Intestinal Neuroendocrine Tumor Surgery: A Cohort Study from the GTE-Endocan-RENATEN Network, the CentralChirSINET Study
4. Olaparib as maintenance therapy in non resectable pancreatic adenocarcinoma associated with homologous recombination deficiency profile: A French retrospective multicentric AGEO real-world study
5. Pacpaint: a histology-based deep learning model uncovers the extensive intratumor molecular heterogeneity of pancreatic adenocarcinoma
6. ASO Visual Abstract: The Need of Centralization for Small Intestinal Neuroendocrine Tumor Surgery—A Cohort Study from the GTE-Endocan-RENATEN Network, the CentralChirSINET Study
7. French guidelines from the GTE, AFCE and ENDOCAN-RENATEN (Groupe d’étude des Tumeurs Endocrines/Association Francophone de Chirurgie Endocrinienne/Reseau national de prise en charge des tumeurs endocrines) for the screening, diagnosis and management of Multiple Endocrine Neoplasia Type 1
8. Appropriate use of morphological imaging for assessing treatment response and disease progression of neuroendocrine tumors
9. Classification of PRSS1 variants responsible for chronic pancreatitis: An expert perspective from the Franco-Chinese GREPAN Study Group
10. Immunophenotypic and molecular characterization of pancreatic neuroendocrine tumors producing serotonin
11. Patterns of Use and Clinical Outcomes with Long-Acting Somatostatin Analogues for Neuroendocrine Tumors: A Nationwide French Retrospective Cohort Study in the Real-Life Setting
12. Actualités dans le traitement néoadjuvant du cancer du pancréas.
13. Efficacy of treatments for VIPoma: A GTE multicentric series
14. Correction to: Patterns of Use and Clinical Outcomes with Long-Acting Somatostatin Analogues for Neuroendocrine Tumors: A Nationwide French Retrospective Cohort Study in the Real-Life Setting
15. Serotonin immunoreactive pancreatic neuroendocrine neoplasm associated with main pancreatic duct dilation: a recognizable entity with excellent long-term outcome
16. Outcome on Mesenteric Mass Response of Small-Intestinal Neuroendocrine Tumors Treated by 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy: The MesenLuth Study, a National Study from the French Group of Endocrine Tumors and Endocan-RENATEN Network
17. Abstract B064: Redefining phenotypic heterogeneity of pancreatic ductal adenocarcinoma: A bottom-up approach
18. Outcome on Mesenteric Mass Response of Small-Intestinal Neuroendocrine Tumors Treated by177Lu-DOTATATE Peptide Receptor Radionuclide Therapy: The MesenLuth Study, a National Study from the French Group of Endocrine Tumors and Endocan-RENATEN Network
19. Characteristics and treatment options of glucagonomas: a national study from the French Group of Endocrine Tumors and ENDOCAN-RENATEN network
20. Correction to: Patterns of Use and Clinical Outcomes with Long-Acting Somatostatin Analogues for Neuroendocrine Tumors: A Nationwide French Retrospective Cohort Study in the Real-Life Setting
21. Redefining phenotypic intratumor heterogeneity of pancreatic ductal adenocarcinoma: a bottom-up approach
22. Diagnostic challenges of pancreatic acinar cystic transformation: a single-centre retrospective study of 64 patients
23. European Neuroendocrine Tumour Society (ENETS) 2023 guidance paper for nonfunctioning pancreatic neuroendocrine tumours
24. ASO Visual Abstract: The Need of Centralization for Small Intestinal Neuroendocrine Tumor Surgery—A Cohort Study from the GTE-Endocan-RENATEN Network, the CentralChirSINET Study
25. Systematic Resection of the Visible Scar After Incomplete Endoscopic Resection of Rectal Neuroendocrine Tumors
26. French guidelines from the GTE, AFCE and ENDOCAN-RENATEN (Groupe d’étude des Tumeurs Endocrines / Association Française de Chirurgie Endocrinienne / REseau NAtional de prise en charge des Tumeurs ENdocrines) for the screening, diagnosis and management of Multiple Endocrine Neoplasia Type 1
27. High Tumor Uptake on18F-FDOPA PET/CT Indicates Poor Prognosis in Patients with Metastatic Midgut Neuroendocrine Tumors: A Study from the Groupe d’étude des Tumeurs Endocrines and ENDOCAN-RENATEN Network
28. Classification of PRSS1 variants responsible for chronic pancreatitis: An expert perspective from the Franco-Chinese GREPAN Study Group
29. Management and outcomes of carcinoid heart disease with liver metastases of midgut neuroendocrine tumours
30. Proposal of early CT morphological criteria for response of liver metastases to systemic treatments in gastroenteropancreatic neuroendocrine tumors: Alternatives to RECIST
31. Systematic Resection of the Visible Scar After Incomplete Endoscopic Resection of Rectal Neuroendocrine Tumors.
32. Management and outcomes of carcinoid heart disease with liver metastases of midgut neuroendocrine tumours.
33. Supplementary Tables from Tumor Growth Rate as a Validated Early Radiological Biomarker Able to Reflect Treatment-Induced Changes in Neuroendocrine Tumors: The GREPONET-2 Study
34. Supplementary Figure 4 from Prognostic Relevance of Pancreatic Adenocarcinoma Whole-Tumor Transcriptomic Subtypes and Components
35. Supplementary Figure 1 from Prognostic Relevance of Pancreatic Adenocarcinoma Whole-Tumor Transcriptomic Subtypes and Components
36. Supplementary Figure 3 from Prognostic Relevance of Pancreatic Adenocarcinoma Whole-Tumor Transcriptomic Subtypes and Components
37. Supplementary Figure 2 from Prognostic Relevance of Pancreatic Adenocarcinoma Whole-Tumor Transcriptomic Subtypes and Components
38. Carcinoid heart disease in patients with midgut neuroendocrine tumours
39. Proposal of early CT morphological criteria for response of liver metastases to systemic treatments in gastroenteropancreatic neuroendocrine tumors:Alternatives to RECIST
40. European Neuroendocrine Tumour Society (ENETS) 2023 guidance paper for nonfunctioning pancreatic neuroendocrine tumours
41. Une tumeur neuroendocrine pancréatique kystique bien spéciale
42. High Tumor Uptake on 18F-FDOPA PET/CT Indicates Poor Prognosis in Patients with Metastatic Midgut Neuroendocrine Tumors: A Study from the Groupe d'étude des Tumeurs Endocrines and ENDOCAN-RENATEN Network.
43. When it comes to chromogranin A, not all clones are made equal
44. Chemotherapy in advanced pancreatic adenosquamous carcinoma: A retrospective multicenter AGEO study
45. Efficacy and tolerance of LV5FU2-carboplatin chemotherapy in patients with advanced pancreatic ductal adenocarcinoma after failure of standard regimens
46. Volumetric Enhancing Tumor Burden at CT to Predict Survival Outcomes in Patients with Neuroendocrine Liver Metastases after Intra-arterial Treatment
47. Spatial and temporal heterogeneity of digestive neuroendocrine neoplasms
48. FOLFOX‐bevacizumab chemotherapy in patients with metastatic neuroendocrine tumors
49. Laparoscopic-assisted liver transplantation: A realistic perspective
50. Identification of protease-sensitive but not misfolding PNLIP variants in familial and hereditary pancreatitis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.